Chronic Coronary Syndrome Real Practice and Guidelines

Chronic Coronary Syndrome...real Practice and Guidelines...A Single Center Registery

Evaluate Adherence to the 2019 ESC Guidelines and standard care protocols for managing patients with the chronic coronary syndrome within the center

Study Overview

• Status: Active, not recruiting
• Conditions: Coronary Arterial Disease (CAD)
• Intervention / Treatment: Drug: Statins (atorvastatin or simvastatin)

Detailed Description

Coronary artery disease (CAD) refers to the presence of atherosclerotic plaques in the coronary arteries, Which can be non-obstructive or obstructive. It represents a major cause of morbidity, mortality, Hospitalization and health expenditure.

The most recent European Guidelines for the diagnosis and management of CCS delineate six common CCS scenarios: patients with suspected CAD and stable angina symptoms and/or dyspnea; patients with new onset of heart failure or left ventricular dysfunction and suspected CAD; asymptomatic and symptomatic patients with stabilized symptoms within one year after an acute coronary syndrome, or patients with recent revascularisation; asymptomatic and symptomatic patients beyond one year after initial diagnosis or revascularisation; Patients with angina and suspected vasospastic or microvascular disease; Asymptomatic subjects in whom CAD is detected at screening. Although these scenarios are heterogeneous, they are associated with an increased risk of acute events, and the stability of CCS patients over time depends on prompt diagnosis, optimal treatment and secondary prevention strategies, including Lifestyle modifications, and pharmacotherapy.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Cardiology Department Assiut University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients with angina and/or dyspnea, and suspected coronary artery disease. Patients with new onset of heart failure or reduced left ventricular function. Patients within 1 year after an acute coronary syndrome or recent revascularization.

Patients beyond 1 year after initial diagnosis or revascularization. Patients with ANOCA (e.g., microvascular angina, vasospastic angina). Asymptomatic subjects referred for screening for coronary artery disease.

Description

Inclusion criteria

Adult patients (18 years or older) with a confirmed or suspected diagnosis of CCS, fall within one of the following broad CCS categories:

• Patients with angina and/or dyspnea, and suspected coronary artery disease.
• Patients with new onset of heart failure or reduced left ventricular function.
• Patients within 1 year after an acute coronary syndrome or recent revascularization.
• Patients beyond 1 year after initial diagnosis or revascularization.
• Patients with ANOCA (e.g., microvascular angina, vasospastic angina).
• Asymptomatic subjects referred for screening for coronary artery disease.

Exclusion Criteria:

• Patients with a recent acute coronary syndrome (defined as those within 1 month of a diagnosis of unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
effect of revasculariztion strategies on chronic coronary syndrome patients	6 months

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2024
• Primary Completion (Estimated): October 22, 2025
• Study Completion (Estimated): October 22, 2025

Study Registration Dates

• First Submitted: October 24, 2024
• First Submitted That Met QC Criteria: November 10, 2024
• First Posted (Estimated): November 12, 2024

Study Record Updates

• Last Update Posted (Estimated): November 12, 2024
• Last Update Submitted That Met QC Criteria: November 10, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: chronic coronary syndrome
• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Atorvastatin; Simvastatin
• Other Study ID Numbers: Chronic coronary Syndrome

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No